Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Domenico Lorusso
Observed name:
D. Lorusso
Institution:
University of Foggia
Observed institutions:
Università Cattolica del Sacro Cuore,
University of Foggia,
Humanitas University,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0009-0000-5892-3703
Observed ORCID:
0009-0000-5892-3703
OpenAlex ID:
A5065867901
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
2024
·
S. Pignata
, D. Califano
, et al.
·
Annals of Oncology
·
41
PDF
Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3
2020
·
D.M. O'Malley
, A.M. Oza
, et al.
·
Gynecologic Oncology
·
4
LBA45 ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + nab-paclitaxel in the subgroup of patients with platinum-resistant ovarian cancer (PROC) previously exposed to a PARP inhibitor
2025
·
D. Lorusso
, S. Quesada
, et al.
·
Annals of Oncology
·
3
PDF
31P Survival outcomes in BRCA pathogenetic mutated, variant of unknown significance, and wild type ovarian cancer patients treated with PARP inhibitors
2022
·
L. Musacchio
, C. Marchetti
, et al.
·
Annals of Oncology
·
1
PDF
Teaching Literature in the Digital Age: The Role of BookTok and Emotions in Increasing Reading
2026
·
Domenico Lorusso
·
Communications in computer and information science
Architectural Barriers and Accessibility: A Systematic Review
2026
·
Francesco Pio Savino
, Lucia Melchiorre
, et al.
·
Communications in computer and information science
Digital Mirrors: How Visual Content on Social Media Shapes Empowerment and Approval
2026
·
Rita Carmela Fabiola Imperatrice
, Lucia Melchiorre
, et al.
1070P Quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) results from the PRIMA/ENGOT-OV26/GOG-3012 final analysis
2025
·
H. Denys
, D.M. Chase
, et al.
·
Annals of Oncology
47MO The risk index of early relapse defined by MiROvaR, a miRNA-based classifier, is a potential predictive marker for bevacizumab benefit: A MITO-MANGO-ENGOT study
2024
·
M. Bagnoli
, L. De Cecco
, et al.
·
ESMO Open
PDF
132P Genomic profiling of primary and recurrent ovarian cancers: A retrospective single-center experience
2022
·
E. Giudice
, V. Ghizzoni
, et al.
·
Annals of Oncology
PDF
Acknowledgement to the Reviewers
2008
·
Hiroshi Nokihara
, Noboru Yamamoto
, et al.
·
Oncology
PDF
Show more works
View as search
Works count:
11
Citation count:
49
H-index:
3
I10-index:
1
Year
Topic
Type